Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...
The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with ...
Pharmaceutical Technology on MSN1d
Supernus’s stock sinks after depression drug fails trialThe company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
GlobalData on MSN2d
AlzeCure Pharma secures €2.5m grant for Phase IIa trial of Alzheimer’s treatmentThe trial will explore the effects of higher doses of ACD856, building on the drug’s established safety profile.
Bonus Biogroup has received FDA approval for an IND application to conduct a Phase III clinical trial of a drug designed to treat acute respiratory distress syndrome (ARDS), especially in severe COVID ...
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...
Stockhead on MSN3d
Recce soars on phase II skin infection trial resultsRecce Pharmaceuticals is up ~9% today after reporting positive patient data analysis from its phase II clinical trial of ...
Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...
Neumora Therapeutics Inc. concealed critical issues with its flagship clinical depression drug’s Phase 2 trial, contributing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback